drugset / Trial / NCT05105035
Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The study investigates the effect of 14 days of twice daily doses of ARV-1801 or placebo in combination with meropenem or ceftazidime in patients hospitalized with melioidosis.
Timeline
- Start
- 2022-06-14
- Primary completion
- 2023-10-10
- Completion
- 2023-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sodium fusidate | Unknown | 600 mg | Oral |
| Background | Ceftazidime | Small molecule | — | Intravenous |
| Background | Meropenem | Small molecule | — | Intravenous |